OncoMatch/Clinical Trials/NCT06481592
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Is NCT06481592 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Lifileucel for endometrial cancer.
Treatment: Lifileucel — The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Must have received: anti-pd-1/pd-l1 therapy
Lab requirements
Cardiac function
adequate cardiopulmonary function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Honor Health · Phoenix, Arizona
- University of Southern California · Los Angeles, California
- Orlando Health · Orlando, Florida
- H. Lee Moffitt Cancer Center and Research Institute, Inc. · Tampa, Florida
- Augusta University · Augusta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify